LABCORP HOLDINGS INC. — Form 8-K
Filed October 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Labcorp reported Q3 2026 revenue of $3.81B (up 6.9% YoY) and adjusted EPS of $4.78 (up 14.5% YoY), prompting upward guidance: enterprise revenue growth raised to 5.9%–6.7% (midpoint +50bps) and adjusted EPS raised to $18.30–$18.70 (midpoint +$0.18). The company announced or closed four acquisitions totaling ~$255.5M in Q3: MLM Medical Labs (closed), and three signed agreements for BioReference Health assets, Myriad Genetics' Prenatal Health business, and Millennium Health (pending regulatory approval). FDA approved PGDx elio tissue CDx for advanced melanoma. Diagnostics segment revenue grew 6.5% organically; Biopharma grew 9.6% organically with backlog of $8.92B (up 3.9% YoY).
Why this rating
Guidance raise and organic growth acceleration are meaningful for a $21.7B company; M&A strategy ($255.5M+ deployed) is moderate-scale but accretive near-term; FDA approvals reinforce specialty testing leadership but are routine for the business.
See more from October 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.